ClinicalTrials.gg

Program

MRNA-1982

A development code. Also written as “mRNA-1982”.

Its studies are mostly in Lyme Disease, led by Moderna.

Furthest: phase 2, since Jul 26, 20232 company-led studies, 1 open or runningNext primary completion: Nov 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna21 open or runningphase 2since Jul 26, 2023Jul 26, 2023Nov 9, 2028phase 2 · NCT07561294

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2023First study: phase 2 study in Lyme DiseaseFirst studyNCT05975099 · 807 enrolled · United States
  2. Apr 24, 2026Phase 2 study in Lyme DiseaseNCT07561294 · 366 enrolled · Canada

Ahead

  1. Nov 9, 2028Primary completion: phase 2 study in Lyme DiseaseNCT07561294

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07561294Lyme Disease · Canada2Active, not recruitingNov 9, 2028366
NCT05975099Lyme Disease · United States2CompletedMay 30, 2025807

How it is read

Names in the registry

  • “mRNA-1982”, 2 entries

Codes read as this program: MRNA1982.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.